Valbonne, France, April 26, 2018, 6.30pm CEST
TxCell SA (FR0010127662 – TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today announces that its annual general meeting of shareholders held in Valbonne approved all proposed resolutions.
The quorum amounted to over 54%, with a number of 11,948,444 expressed votes, out of a total 21,831,009 voting rights.
All resolutions proposed by the management were voted in accordance with recommendations from the board of directors, with more than 94% of the voting rights. Details of votes are available on the company’s website: www.txcell.com.
During the meeting, the terms of corporate officers of François Meyer Ph.D, Auriga Partners, Bpifrance Investissement and David Horn Solomon Ph.D were renewed for a period of four years until the ordinary general meeting that will vote on the financial statements for the financial year ending on December 31, 2021.
In addition, Stéphane Boissel’s mandate as CEO was renewed by the board of directors for a period of three years until the ordinary general meeting that will vote on the financial statements for the financial year ending on December 31, 2020.
“During the general meeting, shareholders reiterated their continued support of the strategy set by the board of directors and executed by the management at TxCell,” said François Meyer, Executive Chairman of the Board of Directors, TxCell. “The board of directors is convinced that the decision to focus TxCell’s research activities on the engineering of Tregs will lead to an improved Treg platform. TxCell is making significant progress and is on the right path to succeed.”
“I would like to thank the board of directors as well as the shareholders for their continuous support through the process of turning TxCell around strategically,” said Stéphane Boissel, CEO, TxCell. “We are strongly encouraged by the data obtained so far. Industry’s interest for Tregs as a therapeutic has never been so high and we see traction for TxCell’s positioning. In just 18 months we have put a new team in place and we believe to have demonstrated the proof of concept for CAR-Tregs, created a robust and scalable manufacturing process as well as a portfolio of patents to efficiently leverage on in the coming years.”